Kairos Pharma KAPA Income Statement (2023-2025)

NYSE KAPA
$0.30 -0.01 (-3.52%)
As of: Aug 20, 2026 · 3:54 PM EDT
1Y3Y5Y7Y10YAll
Download Data
Income Statement Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Dec2025
Revenue & cost
Revenue (Quarter) 50.00M50.00M50.00M
Operating items
Research & Development (Quarter) 0.03M0.01M0.17M0.06M0.01M0.17M0.49M0.50M
Selling, General & Administrative (Quarter) 0.25M1.08M0.12M0.16M0.37M1.27M0.77M0.96M
Operating Expenses (Quarter) 0.29M1.09M0.29M0.22M0.38M1.45M1.27M1.46M
Operating Income (Quarter) -0.29M-1.09M-0.29M-0.22M-0.38M-1.45M-1.27M-1.46M
EBIT (Quarter) -0.29M-1.09M-0.29M-0.22M-0.38M-1.45M-1.27M-1.46M
Non-operating items
Interest & Investment Income (Quarter) 0.00M0.03M
Non Operating Income (Quarter) -0.03M-0.03M-0.04M-0.03M-0.66M0.47M0.00M0.03M
Net income details
EBT (Quarter) -0.30M-1.09M-0.30M-0.23M-0.92M-2.08M-1.55M-1.61M
Profit After Tax (Quarter) -0.31M-1.12M-0.32M-0.25M-1.05M-0.98M-1.26M-1.42M
Income from Continuing Operations (Quarter) -0.30M-1.09M-0.30M-0.23M-0.92M-2.08M-1.55M-1.61M
Consolidated Net Income (Quarter) -0.30M-1.09M-0.30M-0.23M-0.92M-2.08M-1.55M-1.61M
Income towards Parent Company (Quarter) -0.30M-1.09M-0.30M-0.23M-0.92M-2.08M-1.55M-1.61M
Net Income towards Common Stockholders (Quarter) -0.30M-1.09M-0.30M-0.23M-0.92M-2.08M-1.55M-1.61M
Additional items
EPS (Basic) (Quarter) -0.03-0.11-0.03-0.02-0.08-0.18-0.10-0.09
EPS (Diluted) (Quarter) -0.03-0.11-0.03-0.02-0.08-0.18-0.10-0.09
Shares Outstanding (Quarter) 10.33M10.38M10.56M10.56M10.91M11.36M15.88M17.21M18.43M
Shares Outstanding (Diluted) (Quarter) 10.33M10.38M10.56M10.56M10.91M11.36M15.88M17.21M18.43M
Shares Outstanding (Entity) (Quarter) 10.33M10.56M10.56M10.56M12.85M11.36M15.83M17.74M20.82M
EBITDA (Quarter) -0.29M-1.09M-0.29M-0.22M-0.38M-1.45M-1.27M-1.46M
Interest Expenses (Quarter) 0.01M0.00M0.02M0.01M0.54M0.64M0.29M0.19M0.81M